HuR controls glutaminase RNA metabolism

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Glutaminase (GLS) is crucial for cancer cell growth and progression.
• HuR (ELAVL1) is an RNA-binding protein that affects mRNA stability and splicing, and is overexpressed in many cancers.
• ELAVL1's role in regulating GLS in breast cancer is not well understood.

Purpose of the Study:

• To investigate the role of HuR (ELAVL1) in regulating glutaminase (GLS) alternative splicing and isoform expression in breast cancer.
• To determine the prognostic significance of ELAVL1 and GLS isoforms in breast cancer patients.
• To evaluate the therapeutic potential of combined GLS and HuR inhibition.

Main Methods:

• Analysis of ELAVL1 expression and its correlation with GLS isoforms (GAC and KGA) in breast cancer tissues.
• ELAVL1 knockdown experiments in breast cancer cell lines.
• Assessment of glutamine metabolism and cell dependence on glutamine.
• Combination therapy studies involving GLS inhibitors and ELAVL1 silencing.

Main Results:

• Elevated ELAVL1 expression correlates with increased levels of GAC and KGA isoforms, associated with poor prognosis.
• ELAVL1 knockdown alters GLS isoform balance, impacting glutamine metabolism and dependence.
• Combined inhibition of GLS and ELAVL1 synergistically reduced breast cancer cell growth and invasion.

Conclusions:

• HuR (ELAVL1) regulates GLS mRNA alternative splicing and isoform translation/stability in breast cancer.
• The interplay between HuR and GLS isoforms represents a potential therapeutic vulnerability in breast cancer.
• Dual inhibition of GLS and HuR presents a promising therapeutic strategy for breast cancer treatment.